The FAERS Public Dashboard and its Value to the Pharmaceutical Industry

FDA Warns of Serious Immune Reaction with Seizure/BPD Medicine Lamotrigine (Lamictal)

FDA D.I.S.C.O.: First Biosimilar Approval for the Treatment of Cancer

FDA Requires New Class Warnings for All Gadolinium-Based Contrast Agents

FDA Review: Adding LABAs to ICS Treatment Does Not Significantly Increase Serious Asthma Outcomes Risk

Pinpointing the Top Questions about Biosimilars in Rheumatology

The FDA's Adverse Event Reporting System (FAERS) Public Dashboard

FDA D.I.S.C.O.: L-Glutamine for Sickle Cell Disease

FDA D.I.S.C.O.: Osimertinib for Non-Small Cell Lung Cancer

FDA D.I.S.C.O.: Two Approvals for ALK-Positive Non-Small Cell Lung Cancer

FDA D.I.S.C.O.: First Tissue/Site Agnostic Cancer Treatment Approval

FDA D.I.S.C.O.: Avelumab in Merkel Cell Carcinoma

FDA D.I.S.C.O.: Niraparib in Ovarian Cancer

FDA D.I.S.C.O.: Rucaparib in Ovarian Cancer

FDA Confirms Leg and Foot Amputation Risk with Diabetes Medicine Canagliflozin

Introducing FDA's Drug Information Soundcast in Clinical Oncology (DISCO)

FDA Restricts Use of Prescription Codeine and Tramadol Pain Medicines in Children

New Safe Use Requirements for Long-Acting Beta-Agonists (LABAs)

FDA: Product Confusion with Maalox Total Relief and Maalox Liquid Products

FDA: Advisory on Body Building Products